The IL1R1 Knockout SK-OV-3 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-OV-3 ovarian adenocarcinoma cell line. This product comprises a heterogeneous pool of cells harboring targeted disruption of the IL1R1 gene, eliminating expression of the interleukin-1 receptor type 1. The polyclonal format avoids clonal bias and provides a robust loss-of-function model for studying IL-1 signaling in an ovarian cancer background.
The SK-OV-3 parental line was originally isolated from the ascitic fluid of a patient with ovarian carcinoma. These epithelial cells are tumorigenic in nude mice and are extensively employed as a model for ovarian tumor biology, including investigations into proliferation, metastasis, and drug sensitivity. SK-OV-3 retains key oncogenic pathways and is a standard platform for preclinical cancer research.
IL1R1 encodes the primary receptor for IL-1?? and IL-1??. Ligand engagement promotes heterodimerization with the co-receptor IL1RAP, triggering intracellular recruitment of MYD88, IRAK1, and IRAK4. This assembly activates TRAF6 and TAK1, leading to IKK complex (CHUK, IKBKB, IKBKG) phosphorylation and subsequent NF-??B activation. Concurrently, MAPK pathways are stimulated, inducing transcription of inflammatory targets such as NFKBIA, TNFA, IL6, PTGS2, MMPs, and CXCL8. Regulation is exerted by the inhibitor IL1RN and modulators TOLLIP and SIGIRR. CRISPR-mediated disruption of IL1R1 therefore abolishes both NF-??B and MAPK signaling downstream of IL-1??/??.
In SK-OV-3 ovarian cancer cells, IL-1 signaling contributes to tumor cell proliferation, invasion, and the formation of an inflammatory microenvironment. Knockout of IL1R1 provides a genetic model to directly assess these IL-1-dependent effects. By comparing knockout and wild-type cells, researchers can delineate the specific role of IL-1 in driving NF-??B and MAPK activity, cytokine secretion, and metastatic behavior, thereby clarifying its contribution to ovarian adenocarcinoma pathobiology.
Applications for this polyclonal knockout population include mechanistic studies of IL-1-driven inflammation in ovarian cancer, using Western blot for phospho-I??B?? or NF-??B, RT-qPCR for IL6 and CXCL8, and ELISA for secreted cytokines. The cells support NF-??B luciferase reporter, proliferation (MTS/CCK-8), and Transwell migration/invasion assays. They are also suitable for drug screening of IL-1 pathway inhibitors and co-culture assays with immune cells to evaluate tumor-immune interactions. For further information, please contact Ascent Research.
